Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

81.42
-0.2760-0.34%
Post-market: 81.580.1600+0.20%19:30 EDT
Volume:241.06K
Turnover:19.60M
Market Cap:3.55B
PE:- -
High:81.75
Open:81.56
Low:81.15
Close:81.70
52wk High:85.46
52wk Low:64.30
Shares:43.55M
Float Shares:43.50M
Volume Ratio:1.06
T/O Rate:0.55%
Dividend:1.02
Dividend Rate:1.25%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck & Co Exec Says Timing for Raising the $70 Bln Forecast is "to be Determined" Adds "It's Coming"

THOMSON REUTERS
·
Sep 15

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Sep 15

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Sep 15

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Sep 15

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Sep 15

UnitedHealth Earnings Growth Outlook Unlikely to Change, UBS Says

MT Newswires Live
·
Sep 14

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

Evercore ISI Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Cabaletta Bio Boosts Cash Through Warrant Exercises

TIPRANKS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14